SalioGen Therapeutics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
SalioGen Therapeutics was a Lexington, Massachusetts biotech developing Gene Coding, a new category of genetic medicine. Its platform used a mammal-derived enzyme called saliogase to insert DNA sequences of any size into precise genomic locations without causing double-strand breaks or relying on viral vectors — removing the ceiling on genetic cargo size and enabling repeat dosing. The company initially targeted eye and liver diseases, including inherited retinal disorders, and raised a total of $135 million.
02 / SalioGen Therapeutics FAILURE REASONS
Why it failed
SalioGen was caught in the gene-therapy investment downturn. After burning through its $115 million Series B during the sector-wide funding squeeze, it instituted widespread layoffs reported in October 2024 and scaled back its ambitions to preclinical-stage work, maintaining only a reduced-capacity team to explore strategic options. Company-data provider PrivCo now describes it as no longer operating. No formal bankruptcy filing or dated shutdown announcement was found, so the final event type and year remain unverified.
03 / EVENT HISTORY
Events in the structured record
- Exits stealth
SalioGen exits stealth with a $20 million Series A led by PBM Capital to validate its non-viral gene-therapy platform.
- Series B
The company closes an oversubscribed $115 million Series B in January 2022, co-led by GordonMD Global Investments and EPIQ Capital Group with Fidelity, T. Rowe Price and D1 Capital participating.
- Layoffs and pullback
In October 2024, amid the gene-therapy investment slowdown, SalioGen institutes widespread layoffs and scales back its ambitions. PrivCo later describes the company as no longer operating.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / AFTERMATH
Lessons
SalioGen's arc shows how quickly the gene-editing capital cycle turned: a $135 million war chest and a scientifically differentiated platform were not enough once investor sentiment toward preclinical gene-therapy companies soured. Differentiated science still needs a durable financing bridge across the clinical valley of death.